Crescita Therapeutics Stock Net Income
| CTX Stock | CAD 0.47 0.02 4.08% |
As of the 14th of February 2026, Crescita Therapeutics shows the mean deviation of 1.7, and Risk Adjusted Performance of 0.0085. Crescita Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Crescita Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.0419 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -3.2 M | -3.3 M | |
| Net Loss | -3.2 M | -3.3 M | |
| Net Loss | -3.2 M | -3.3 M | |
| Net Loss | (0.14) | (0.13) | |
| Net Income Per E B T | 1.14 | 1.45 |
Crescita | Net Income |
Evaluating Crescita Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.
Latest Crescita Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Crescita Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Crescita Therapeutics financial statement analysis. It represents the amount of money remaining after all of Crescita Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Crescita Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (2.75 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Crescita Net Income Regression Statistics
| Arithmetic Mean | (7,178,713) | |
| Coefficient Of Variation | (100.15) | |
| Mean Deviation | 6,756,976 | |
| Median | (3,320,625) | |
| Standard Deviation | 7,189,554 | |
| Sample Variance | 51.7T | |
| Range | 17.8M | |
| R-Value | 0.78 | |
| Mean Square Error | 21.7T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | 1,109,467 | |
| Total Sum of Squares | 827T |
Crescita Net Income History
Crescita Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Crescita Therapeutics is extremely important. It helps to project a fair market value of Crescita Stock properly, considering its historical fundamentals such as Net Income. Since Crescita Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crescita Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crescita Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Crescita Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Crescita Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Crescita Therapeutics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Crescita Therapeutics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Crescita Therapeutics or generate 0.0% return on investment in Crescita Therapeutics over 90 days. Crescita Therapeutics is related to or competes with Delivra Health, and Avant Brands. Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug pro... More
Crescita Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Crescita Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Crescita Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.87 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 13.14 | |||
| Value At Risk | (4.55) | |||
| Potential Upside | 4.26 |
Crescita Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crescita Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Crescita Therapeutics' standard deviation. In reality, there are many statistical measures that can use Crescita Therapeutics historical prices to predict the future Crescita Therapeutics' volatility.| Risk Adjusted Performance | 0.0085 | |||
| Jensen Alpha | 7.0E-4 | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0523 |
Crescita Therapeutics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0085 | |||
| Market Risk Adjusted Performance | 0.0623 | |||
| Mean Deviation | 1.7 | |||
| Semi Deviation | 2.51 | |||
| Downside Deviation | 4.87 | |||
| Coefficient Of Variation | 55320.48 | |||
| Standard Deviation | 2.72 | |||
| Variance | 7.38 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 7.0E-4 | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0523 | |||
| Maximum Drawdown | 13.14 | |||
| Value At Risk | (4.55) | |||
| Potential Upside | 4.26 | |||
| Downside Variance | 23.72 | |||
| Semi Variance | 6.32 | |||
| Expected Short fall | (2.82) | |||
| Skewness | (0.66) | |||
| Kurtosis | 1.63 |
Crescita Therapeutics Backtested Returns
As of now, Crescita Stock is abnormally volatile. Crescita Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0263, which signifies that the company had a 0.0263 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Crescita Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Crescita Therapeutics' risk adjusted performance of 0.0085, and Mean Deviation of 1.7 to double-check if the risk estimate we provide is consistent with the expected return of 0.0718%. Crescita Therapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0973, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Crescita Therapeutics are expected to decrease at a much lower rate. During the bear market, Crescita Therapeutics is likely to outperform the market. Crescita Therapeutics right now shows a risk of 2.73%. Please confirm Crescita Therapeutics potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if Crescita Therapeutics will be following its price patterns.
Auto-correlation | -0.05 |
Very weak reverse predictability
Crescita Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Crescita Therapeutics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Crescita Therapeutics price movement. The serial correlation of -0.05 indicates that only as little as 5.0% of current Crescita Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.05 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Crescita Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Crescita Therapeutics reported net income of (2.75 Million). This is 100.81% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all Canada stocks is 100.48% higher than that of the company.
Crescita Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crescita Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Crescita Therapeutics could also be used in its relative valuation, which is a method of valuing Crescita Therapeutics by comparing valuation metrics of similar companies.Crescita Therapeutics is currently under evaluation in net income category among its peers.
Crescita Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Crescita Therapeutics from analyzing Crescita Therapeutics' financial statements. These drivers represent accounts that assess Crescita Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Crescita Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 13.5M | 13.7M | 9.9M | 11.2M | 12.9M | 14.4M | |
| Enterprise Value | 5.0M | 7.0M | 1.8M | 2.7M | 3.1M | 3.0M |
Crescita Fundamentals
| Return On Equity | 0.0283 | ||||
| Return On Asset | -0.0221 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 924.55 K | ||||
| Shares Outstanding | 18.61 M | ||||
| Shares Owned By Insiders | 11.67 % | ||||
| Number Of Shares Shorted | 2 K | ||||
| Price To Earning | 9.37 X | ||||
| Price To Book | 0.54 X | ||||
| Price To Sales | 0.40 X | ||||
| Revenue | 19.58 M | ||||
| Gross Profit | 11.42 M | ||||
| EBITDA | (1.33 M) | ||||
| Net Income | (2.75 M) | ||||
| Cash And Equivalents | 9.27 M | ||||
| Cash Per Share | 0.45 X | ||||
| Total Debt | 834 K | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 3.18 X | ||||
| Book Value Per Share | 0.87 X | ||||
| Cash Flow From Operations | 2.73 M | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | 0.02 X | ||||
| Beta | 0.31 | ||||
| Market Capitalization | 8.87 M | ||||
| Total Asset | 21.78 M | ||||
| Retained Earnings | (45.35 M) | ||||
| Working Capital | 9.79 M | ||||
| Net Asset | 21.78 M |
About Crescita Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crescita Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crescita Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crescita Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Crescita Stock
Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.